T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS

BACKGROUND: Patients with schizophrenia are at increased risk for developing metabolic syndrome, with an estimated prevalence of approximately 35–50% (Correll et al. Psychiatr Serv 2010;61:892–98; Vancampfort et al. World Psychiatry 2015;14:339–47). Treatment with atypical antipsychotic medications...

Descripción completa

Detalles Bibliográficos
Autores principales: Tocco, Michael, Pikalov, Andrei, Hsu, Jay, Cucchiaro, Josephine, Newcomer, John W, Loebel, Antony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888403/
http://dx.doi.org/10.1093/schbul/sby016.281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888403/
http://dx.doi.org/10.1093/schbul/sby016.281

Ejemplares similares